Related Experiment Video

Updated: Jul 23, 2026

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

The role of MEK inhibition in pediatric low-grade gliomas

Shehryar R Sheikh1,2, Laura J Klesse3, Ross Mangum4

  • 1Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, United States.

Frontiers in Oncology
|January 6, 2025
PubMed

Insights

MEK inhibitors offer a promising new treatment for pediatric low-grade gliomas (pLGGs), potentially improving outcomes for children with unresectable tumors and reducing side effects from chemotherapy.

Area of Science:

  • Pediatric oncology
  • Neuro-oncology
  • Molecular targeted therapy

Background:

  • Pediatric low-grade gliomas (pLGGs) are the most prevalent pediatric brain tumors.
  • Current treatments like chemotherapy can lead to significant long-term side effects and tumor recurrence in unresectable cases.

Purpose of the Study:

  • To explore the emerging role of MEK inhibitors in managing pLGGs.
  • To review the molecular rationale, clinical evidence, and challenges associated with MEK inhibitors in pLGG treatment.

Main Methods:

  • Literature review of preclinical and clinical studies on MEK inhibitors for pLGG.
  • Analysis of the molecular pathways targeted by MEK inhibitors in pLGG.
  • Evaluation of current evidence for MEK inhibitor efficacy and safety in pediatric patients.

Main Results:

  • MEK inhibitors target key signaling pathways dysregulated in pLGG.
  • Clinical data suggest potential efficacy of MEK inhibitors in specific pLGG subtypes.
  • Challenges include identifying optimal patient populations and managing potential toxicities.

Conclusions:

  • MEK inhibitors represent a promising therapeutic strategy for pLGGs, offering an alternative to traditional chemotherapy.
  • Further research is needed to refine treatment protocols and address challenges for widespread clinical adoption.
Keywords:
MAPKMEKMEKiPLGGpediatric low grade gliomatargeted therapy

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response09:43

Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

Published on: May 17, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...